八正散治疗化学性膀胱炎
|
摘要
目的:观察八正散治疗化学性膀胱炎的临床疗效及安全性。方法:90例化学性膀胱炎患者随机分为治疗组和对照组,每组45例。治疗组给予中药八正散,对照组予西医常规治疗,持续治疗12周。分别于治疗前及治疗后测量O'Leary Saint症状指数、问题指数评分及6个月化疗完成率。结果:两组患者治疗后O'Leary Saint症状指数、问题指数评分比较,差异有统计学意义(P <0. 05)。治疗组6个月化疗完成率91%,对照组为73%,两组比较,差异有统计学意义(P <0. 05)。结论:八正散治疗化学性膀胱炎临床疗效明确,可降低O'Leary Saint症状指数、问题指数评分。
Objective: To observe the clinical efficacy and safety of Bazheng Powder in the treatment of chemical cystitis. Methods:90 patients with chemical cystitis were randomly divided into treatment group and control group,45 cases in each group. The treatment group was treated with Bazheng Powder,while the control group was treated with routine western medicine for 12 weeks. O'Leary Saint symptom index and O'Leary Saint problem index scores and 6-month chemotherapy completion rate were measured before and after treatment. Results: There was significant difference in O'Leary Saint symptom index and O'Leary Saint problem index scores between the two groups after treatment. The difference was statistically significant( P < 0. 05). The 6-month completion rate of chemotherapy in the treatment group was 91% and that in the control group was 73%. There was a significant difference between the two groups( P < 0. 05). Conclusion: Bazheng Powder has a definite clinical effect in the treatment of chemical cystitis,which can reduce O'Leary Saint symptom index and O'Leary Saint problem index scores.
Objective: To observe the clinical efficacy and safety of Bazheng Powder in the treatment of chemical cystitis. Methods:90 patients with chemical cystitis were randomly divided into treatment group and control group,45 cases in each group. The treatment group was treated with Bazheng Powder,while the control group was treated with routine western medicine for 12 weeks. O'Leary Saint symptom index and O'Leary Saint problem index scores and 6-month chemotherapy completion rate were measured before and after treatment. Results: There was significant difference in O'Leary Saint symptom index and O'Leary Saint problem index scores between the two groups after treatment. The difference was statistically significant( P < 0. 05). The 6-month completion rate of chemotherapy in the treatment group was 91% and that in the control group was 73%. There was a significant difference between the two groups( P < 0. 05). Conclusion: Bazheng Powder has a definite clinical effect in the treatment of chemical cystitis,which can reduce O'Leary Saint symptom index and O'Leary Saint problem index scores.
引文
[1]陈丽周,陈益展.膀胱灌注化疗后并发症的观察及护理[J].中外医学研究,2012,10(28):64-65.
[2]LUM B L,TORTI F M.Adjuvant intravesicular pharmacotherapy for superficial bladder cancer[J].J Natl Cancer Inst,1991,83(10):682-694.
[3]FILSON C P,MONTGOMERY J S,DAILEY S M,et al.Complications associated with single-dose,perioperative mitomycin-C for patients undergoing bladder tumor resection[J].Urol Oncol,2014,32(1):1-8.
[4]汤祺,陈亚娟.经尿道等离子双极膀胱肿瘤电切术联合膀胱灌注化疗治疗表浅性膀胱癌29例[J].中国保健营养(下旬刊),2013,23(1):174.
[5]李昌勤,于海林,康文艺,等.八正散的现代临床应用概述[J].中成药,2010,32(5):840-844.
[6]代睿欣,吕立国,张磊,等.清热利湿法治疗膀胱灌注化疗所致化学性膀胱炎临床初探[J].中国现代药物应用,2012,6(16):80-81.
[7]黄英.膀胱肿瘤术后吡柔比星膀胱灌注治疗的观察及护理[J].内蒙古中医药,2013,32(26):155.
[8]金碧霞,刘丽霞,叶丽敏.膀胱肿瘤患者中断膀胱灌注治疗的原因分析及护理对策[J].护理与康复,2010,9(7):587-588.
[9]COOKSON M S,CHANG S S,LIHOU C,et al.Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer,including carcinoma in situ of the bladder[J].Ther Adv Urol,2014,6(5):181-191.
[10]潘英.八正散加减治疗膀胱炎35例观察[J].实用中医内科杂志,2006,20(1):85.
[2]LUM B L,TORTI F M.Adjuvant intravesicular pharmacotherapy for superficial bladder cancer[J].J Natl Cancer Inst,1991,83(10):682-694.
[3]FILSON C P,MONTGOMERY J S,DAILEY S M,et al.Complications associated with single-dose,perioperative mitomycin-C for patients undergoing bladder tumor resection[J].Urol Oncol,2014,32(1):1-8.
[4]汤祺,陈亚娟.经尿道等离子双极膀胱肿瘤电切术联合膀胱灌注化疗治疗表浅性膀胱癌29例[J].中国保健营养(下旬刊),2013,23(1):174.
[5]李昌勤,于海林,康文艺,等.八正散的现代临床应用概述[J].中成药,2010,32(5):840-844.
[6]代睿欣,吕立国,张磊,等.清热利湿法治疗膀胱灌注化疗所致化学性膀胱炎临床初探[J].中国现代药物应用,2012,6(16):80-81.
[7]黄英.膀胱肿瘤术后吡柔比星膀胱灌注治疗的观察及护理[J].内蒙古中医药,2013,32(26):155.
[8]金碧霞,刘丽霞,叶丽敏.膀胱肿瘤患者中断膀胱灌注治疗的原因分析及护理对策[J].护理与康复,2010,9(7):587-588.
[9]COOKSON M S,CHANG S S,LIHOU C,et al.Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer,including carcinoma in situ of the bladder[J].Ther Adv Urol,2014,6(5):181-191.
[10]潘英.八正散加减治疗膀胱炎35例观察[J].实用中医内科杂志,2006,20(1):85.